Functionally, CAFs-derived THBS2 promoted the aggressive phenotype by presumably modulating both cancer cells and tumor immunity, identifying THBS2+ CAFs as a candidate therapeutic target in early-stage LUAD. This evidence concerns the gene THBS2 and neoplasm.